Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2013-02-11

Clinical Trial Update: Suboptimal Responders to Adefovir Switching to Entecavir [Phase 4]

View source ↗

Summary

Phase 4 trial update on chronic hepatitis B patients who were suboptimal responders to adefovir and switched to entecavir; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Baraclude (entecavir)
  • Hepsera (adefovir dipivoxil)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis B, Chronic | Phase 4 | Status: COMPLETED | Results posted: 2013-02-11